Celcuity Inc. (CELC)

Celcuity's stock price has increased significantly in the past six months due to positive clinical progress for gedatolisib. Key events include positive Phase 3 data for gedatolisib, the submission of a New Drug Application (NDA) to the FDA, analyst coverage and price target increases, and financing activities, including raising $287 million through public offerings and amending its senior secured term loan facility.

As a clinical-stage biotechnology company, Celcuity Inc. currently generates negligible revenue from commercial operations and direct demand seasonality for its products and services in a commercial sense is not applicable at this stage. The company's operations are primarily sustained through capital raises and strategic financing to fund its extensive clinical development.

Celcuity, Inc. is a clinical-stage biotechnology company focused on transforming cancer treatment through targeted therapies and diagnostics. The company is developing gedatolisib for various solid tumors, with initial programs focusing on breast and prostate cancer. Celcuity also develops the CELsignia companion diagnostic platform to match cancer patients with effective targeted therapies and has a license agreement with Pfizer Inc. for gedatolisib.

Celcuity, Inc. is headquartered in Minneapolis, Minnesota, United States. Its clinical development programs for gedatolisib include patients in the U.S., Canada, Western Europe, and Asia Pacific.

Celcuity's brand reputation appears strong and positive, driven by the clinical advancements of gedatolisib. The overwhelmingly positive analyst consensus and substantial increase in stock price indicate strong investor confidence. The FDA granting gedatolisib Breakthrough Therapy Designation further enhances its reputation.

The ownership structure of Celcuity is predominantly institutional, with approximately 62.78% to 76.71% of the company's stock owned by institutional investors, while insiders hold around 15.78% to 25.66%, and public companies and individual investors hold a smaller percentage (3.60% to 8.03%). Major institutional owners include Baker Bros. Advisors Lp, Perceptive Advisors Llc, and BlackRock, Inc. Notable individual insiders include Brian F. Sullivan and Dr. Lance G. Laing.